CORDIS
EU research results

CORDIS

English EN
Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE

Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE

Objective

The BERENICE consortium is aiming at providing a new and cost-effective solution to a better treatment for Chagas chronic patients. Please see its objectives below :

Main objective
• Obtain a more effective, better tolerated and cheaper formulation of a drug with trypanocidal activity to cure Chagas disease

Specific Objectives
• Obtain results of pharmacokinetics of new formulations
• Assess trypanocidal activity of new formulations in vitro and in animal model
• Involve partners, research and industry in endemic countries to promote technology transfer and promote in-site solutions at cheaper cost.
The foreseen results of this project would have firstly an impact on the better comprehension and control of the SUVs behavior as drug delivery nanodevices for the specific APIs to be conjugated. If this conjugation is successful, further impacts are expected dealing with technology transfer issues, such as scale-up of the corresponding SUVs preparation methodology and its implementation at industrial scale.
Apart from including stong participation from endemic countries's institutions, the consortium also involves private companies, thus enabling the participation of all the key actors of the chain to confront and control better Chagas disease. The innovative approach, through the new developed nano- and microparticles based formulations will have an important impact on the safety of the medicament since the therapeutic efficacy will increase and consequently the doses needed and the incidences caused by adverse effects will be reduced.

Coordinator

INSTITUT CATALA DE LA SALUT

Address

Gran Via De Les Corts Catalanes 587
08007 Barcelona

Spain

Activity type

Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

EU Contribution

€ 1 092 805,17

Administrative Contact

Joan X. Comella (Dr.)

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUTO DE HIGIENE E MEDICINA TROPICAL

Portugal

CENTRO DE INVESTIGACION BIOMEDICA EN RED BIOINGENIERIA, BIOMATERIALES Y NANOMEDICINA

Spain

EU Contribution

€ 456 627,20

CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.

Spain

EU Contribution

€ 100 518,75

FUNDACAO OSWALDO CRUZ

Brazil

EU Contribution

€ 374 638

UNIVERSIDADE NOVA DE LISBOA

Portugal

EU Contribution

€ 280 000

ADMINISTRACION NACIONAL DE LABORATORIOS E INSTITUTOS DE SALUD DR. CARLOS G. MALBRAN

Argentina

EU Contribution

€ 173 147,83

UNIVERSITAT DE BARCELONA

Spain

EU Contribution

€ 250 999,92

PRAXIS PHARMACEUTICAL FRANCE SARL

France

EU Contribution

€ 71 677,83

LABORATORIO ELEA SOCIEDAD ANONIMA COMERCIAL, INDUSTRIAL, FINANCIERA Y AGROPECUARIA

Argentina

EU Contribution

€ 75 230,53

BIOKERALTY RESEARCH INSTITUTE AIE

Spain

EU Contribution

€ 122 571,77

Project information

Grant agreement ID: 305937

Status

Closed project

  • Start date

    1 September 2012

  • End date

    31 August 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 900 977,04

  • EU contribution

    € 2 998 217

Coordinated by:

INSTITUT CATALA DE LA SALUT

Spain